Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2024 08:35 ET | Source: GRI Bio, Inc.

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

Data presented at the 14th International Congress on Autoimmunity Encouraging preclinical data observed to date on par with OFEV® (nintedanib), a leading tyrosine kinase inhibitor with 2025...
May 20, 2024 08:45 ET | Source: GRI Bio, Inc.

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score...
May 14, 2024 09:05 ET | Source: GRI Bio, Inc.

GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase

Live webcast fireside chat on Tuesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company...
May 13, 2024 08:00 ET | Source: GRI Bio, Inc.

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024 ...
April 29, 2024 08:45 ET | Source: GRI Bio, Inc.

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
April 25, 2024 09:15 ET | Source: GRI Bio, Inc.

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Live webcast on Wednesday, May 1st at 3:00 PM ET LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...
April 16, 2024 08:35 ET | Source: GRI Bio, Inc.

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovation Continued advancement of an innovative pipeline of NKT cell...
April 08, 2024 08:35 ET | Source: GRI Bio, Inc.

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
April 01, 2024 07:35 ET | Source: GRI Bio, Inc.

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline data expected H2 2024 ...
March 28, 2024 09:00 ET | Source: GRI Bio, Inc.

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

Live webcast on Wednesday, April 3rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...